NEULAND LABORATORIES
|
The Current P/E Ratio of NEULAND LABORATORIES is 59.61.
| Share Price | ₹16,952.2 | Jun 11,2026 |
| Market Cap | ₹21,698.8 Cr | |
| Earnings-TTM | ₹364.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 59.61x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NEULAND LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹21,698.8 Cr] as on Jun 11,2026
(/) Earnings [ ₹364.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 59.61x ]
Thus, for NEULAND LABORATORIES , the investors are currently willing to pay 59.61 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NEULAND LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NEULAND LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of NEULAND LABORATORIES
PE Ratio Performance Analysis for NEULAND LABORATORIES
- NEULAND LABORATORIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 30.88x.
- NEULAND LABORATORIES 's operated at median p/e ratio of 26.86x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NEULAND LABORATORIES 's p/e ratio peaked in Mar2025 at 59.57x.
- NEULAND LABORATORIES 's p/e ratio hit its five-year low in Mar2023 of 14.12x.
How does NEULAND LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NEULAND LABORATORIES | 364.00 | 59.61 | 21,698.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 37.23 | 430,513.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 68.76 | 176,570.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 72.34 | 154,670.0 |
| CIPLA LTD | 3,869.79 | 28.87 | 111,725.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 25.68 | 106,424.0 |
| MANKIND PHARMA LTD | 1,926.41 | 50.84 | 97,948.2 |
| LUPIN LTD | 5,355.47 | 19.41 | 103,975.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.13 | 111,254.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 24.06 | 84,241.1 |
| LAURUS LABS LTD | 889.85 | 84.42 | 75,121.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NEULAND LABORATORIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 19.41x |
| Max industry PE | 84.42x |
| Median industry PE | 37.23x |
| Average industry PE | 44.85x |
You may also like the below Video Courses